ADC THERAPEUTICS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.3 USD | -5.91% |
|
-12.24% | +159.04% |
| May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
| May. 06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,485 | 1,550 | 306.9 | 134.1 | 413.6 | - | - |
| Enterprise Value (EV) 1 | 2,087 | 1,092 | 90.22 | -20.12 | 283.2 | 324.8 | 413.6 |
| P/E ratio | -8.49 x | -6.73 x | -1.93 x | -0.56 x | -2.33 x | -2.73 x | -3.33 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 45.7 x | 1.46 x | 1.93 x | 5.32 x | 4.48 x | 3.21 x |
| EV / Revenue | - | 32.2 x | 0.43 x | -0.29 x | 3.64 x | 3.52 x | 3.21 x |
| EV / EBITDA | -11,628,787 x | -5,497,765 x | -1,253,468 x | - | - | - | - |
| EV / FCF | - | -4.61 x | -0.66 x | 0.17 x | -3 x | -3.62 x | -27.8 x |
| FCF Yield | - | -21.7% | -152% | 606% | -33.3% | -27.6% | -3.6% |
| Price to Book | 7.32 x | 9.34 x | 3.49 x | - | - | - | - |
| Nbr of stocks (in thousands) | 77,619 | 76,754 | 79,934 | 80,781 | 96,189 | - | - |
| Reference price 2 | 32.01 | 20.20 | 3.840 | 1.660 | 4.300 | 4.300 | 4.300 |
| Announcement Date | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.34 | - | 33.92 | 209.9 | 69.56 | 77.71 | 92.23 | 128.7 |
| EBITDA | - | -179.5 | -198.6 | -71.98 | - | - | - | - |
| EBIT 1 | - | -219.3 | -261.7 | -123.6 | -166 | -138.5 | -134.8 | -119.1 |
| Operating Margin | - | - | -771.65% | -58.9% | -238.63% | -178.17% | -146.2% | -92.55% |
| Earnings before Tax (EBT) 1 | - | -246 | -251.5 | -154.7 | -195.4 | -162.7 | -151.9 | -135.7 |
| Net income 1 | - | -246.3 | -230 | -155.8 | -240.1 | -171.2 | -160.5 | -135.7 |
| Net margin | - | - | -678.2% | -74.22% | -345.11% | -220.35% | -174.05% | -105.39% |
| EPS 2 | -2.360 | -3.770 | -3.000 | -1.990 | -2.940 | -1.843 | -1.575 | -1.290 |
| Free Cash Flow 1 | - | - | -236.8 | -137.4 | -121.9 | -94.4 | -89.8 | -14.9 |
| FCF margin | - | - | -698.2% | -65.44% | -175.25% | -121.47% | -97.36% | -11.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/24/20 | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.01 | 46.5 | 17.29 | 76.32 | 69.8 | 18.99 | 19.28 | 14.49 | 16.79 | 18.05 | 19.02 | 19.88 | 20.34 | 21.27 | 22.34 |
| EBITDA | -15.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -62.78 | -40.36 | -69.41 | -3.114 | -10.74 | -51.57 | -39.79 | -37.4 | -39.98 | -33.61 | -34.61 | -35.07 | -35.96 | -35.66 | -36.06 |
| Operating Margin | -369.08% | -86.81% | -401.43% | -4.08% | -15.38% | -271.55% | -206.34% | -258.08% | -238.11% | -186.19% | -181.92% | -176.43% | -176.79% | -167.64% | -161.44% |
| Earnings before Tax (EBT) 1 | -56.35 | -17.83 | -65.32 | -51.32 | -20.19 | -59.69 | -53.73 | -47.89 | -39.87 | -45.76 | -38.72 | -39.19 | -39.6 | -44.31 | -44.81 |
| Net income 1 | -34.38 | -16.66 | -64.37 | -50.61 | -24.16 | -59.43 | -47.12 | -47.81 | -85.03 | -46.61 | -39.05 | -39.19 | -47.6 | -44.31 | -44.81 |
| Net margin | -202.12% | -35.83% | -372.3% | -66.31% | -34.61% | -312.9% | -244.34% | -329.86% | -506.44% | -258.16% | -205.29% | -197.16% | -234.02% | -208.31% | -200.62% |
| EPS 2 | -0.4500 | -0.2200 | -0.8400 | -0.6500 | -0.3000 | -0.7400 | -0.5800 | -0.5800 | -1.030 | -0.5600 | -0.4196 | -0.4045 | -0.4786 | -0.4267 | -0.4367 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/22 | 5/9/22 | 8/9/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/13/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 397 | 459 | 217 | 154 | 130 | 88.8 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -237 | -137 | -122 | -94.4 | -89.8 | -14.9 |
| ROE (net income / shareholders' equity) | - | -110% | -91.7% | -122% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | -27.2% | -43.9% | -63.2% | -67.1% | - |
| Assets 1 | - | - | - | 573.6 | 546.5 | 271.1 | 239.2 | - |
| Book Value Per Share | - | 4.370 | 2.160 | 1.100 | - | - | - | - |
| Cash Flow per Share | - | -2.580 | - | - | - | - | - | - |
| Capex 1 | - | 0.8 | 3.43 | 0.58 | 3.22 | 4 | 3.9 | 2.6 |
| Capex / Sales | - | - | 10.11% | 0.27% | 4.62% | 5.15% | 4.23% | 2.02% |
| Announcement Date | 4/24/20 | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.3
USD
Average target price
10
USD
Spread / Average Target
+132.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +159.04% | 414M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ADCT Stock
- Financials ADC Therapeutics SA
